Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oxaliplatin and Capecitabine in Unresectable Cholangiocarcinoma
NCT00338988Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Aug 2003
- Primary completion
- May 2009
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 2 trial of oxaliplatin in cholangiocarcinoma (CCA), gallbladder cancer, biliary tract cancer (BTC), sponsored by University of Texas MD Anderson Cancer Center. Started Aug 2003; status: completed.
02
Drugs
oxaliplatin
03
Conditions
cholangiocarcinoma (CCA)gallbladder cancerbiliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT00338988.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00338988.